Understanding Your Baby's Diagnosis: Dyshormonogenic Goiter
At a Glance
Dyshormonogenic goiter is a form of congenital hypothyroidism in which a baby's thyroid is present but cannot make enough hormone. Prompt levothyroxine treatment and regular blood tests support healthy brain development and growth; some DUOX2-related forms may be temporary.
Receiving an abnormal newborn screening result can be an overwhelming experience that sparks immediate worry. It is important to know that you are not alone in this; while the diagnosis of dyshormonogenic goiter sounds complex, it is a well-understood cause of congenital hypothyroidism (an underactive thyroid present from birth) [1][2].
The most vital thing to understand right now is that this condition is highly treatable. When babies begin treatment promptly, they typically grow and develop just as well as any other child [3][4].
What is Dyshormonogenic Goiter?
To understand this condition, it helps to break down the name. A goiter is simply an enlarged thyroid gland [5]. Dyshormonogenic means the “machinery” inside the thyroid gland that makes hormones is not working correctly [1].
Think of the thyroid like a factory. In most cases of congenital hypothyroidism, the factory was never built or was built in the wrong place. In dyshormonogenic goiter, the factory is in the right place and may even be larger than normal, but the assembly line inside is broken [5][6]. Because the body senses there isn’t enough thyroid hormone, it sends signals to the “factory” to work harder, which can cause the gland to grow—creating a goiter [7].
How Common Is It?
Congenital hypothyroidism occurs in approximately 1 in 2,000 to 4,000 newborns worldwide [8][9]. Dyshormonogenic goiter accounts for about 10% to 15% of these cases globally, though in some regions or specific populations, it can account for 40% or even up to 60% of cases [1][2][10].
Why Your Baby Looks “Normal”
It is perfectly normal if your baby looks and acts healthy right now. Most newborns with this condition show no outward signs at birth [11]. While the term “goiter” might make you worry about a large, visible mass on your baby’s neck, this is rarely the case in newborns. In fact, many goiters are only detectable through a thyroid ultrasound (an imaging test using sound waves) and cannot be seen or felt by hand [5].
If symptoms do appear early on, they are often subtle and non-specific, such as:
- Jaundice (a yellowing of the skin or eyes) that lasts longer than usual [11][4].
- Being extra sleepy or having low energy [4].
- Constipation [4].
- Difficulty staying warm [4].
The Importance of Early Treatment
The goal of treatment is to replace the hormone your baby’s thyroid isn’t making enough of. This is done with a daily medication called levothyroxine, which is a synthetic version of the natural thyroid hormone [12].
- Prompt Start: Starting medication as soon as the diagnosis is confirmed is the most important step for protecting your baby’s brain development [12][13].
- Normal Outcomes: When treatment is started early and the hormone levels are kept in the target range, children typically meet all their developmental milestones and lead healthy lives [3][4].
- Goiter Management: Taking the medication correctly often helps the thyroid gland shrink back to a more normal size over time [7][14].
Is This Permanent?
In many cases, this condition is lifelong because it is caused by a permanent genetic change in how the thyroid functions [1][15]. However, some forms (specifically those related to a gene called DUOX2) can sometimes be transient, meaning the thyroid may eventually start working on its own [3][16].
If the endocrinologist suspects a transient form, doctors may wait until a child is about 3 years old before testing to see if the condition is permanent. At that age, the brain is developed enough that it is safer to briefly pause the medication under strict medical supervision to see if the body can maintain its own hormone levels. This trial is not required for every child and must be physician-led [17][18].
What to Expect in the First Month
Your care team will guide you through a typical first-month sequence, which includes:
- Confirmatory Blood Tests: To double-check the newborn screening results with a standard blood draw [19].
- Immediate Medication: Starting levothyroxine right away.
- Early Check: Your first follow-up blood test about 1 to 2 weeks after starting medication to ensure levels are improving.
- Imaging (if directed): An ultrasound or a scintigraphy (a specialized scan) to look at the size and shape of the thyroid, though treatment never waits for this [20].
- Frequent Monitoring: Ongoing blood tests during the first few years of life to ensure your baby’s medication dose is adjusted as they grow [19][4].
While the diagnosis is a lot to process, the medical community has excellent systems in place to support your family. Your proactive steps now are ensuring your baby has the best possible start in life [12].
Common questions in this guide
What does dyshormonogenic goiter mean in a newborn?
Can my baby have dyshormonogenic goiter and still look healthy?
How is dyshormonogenic goiter confirmed after an abnormal newborn screen?
What treatment does a baby with dyshormonogenic goiter need?
Will my baby's dyshormonogenic goiter last for life?
What happens during the first month after my baby is diagnosed?
Can early treatment help my baby develop normally?
Get notified when new evidence is published on dyshormonogenic goiter.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (20)
- 1
Clinical genetics of defects in thyroid hormone synthesis.
Kwak MJ
Annals of pediatric endocrinology & metabolism 2018; (23(4)):169-175 doi:10.6065/apem.2018.23.4.169.
PMID: 30599477 - 2
Next-Generation Sequencing Analysis Reveals Frequent Familial Origin and Oligogenism in Congenital Hypothyroidism With Dyshormonogenesis.
Oliver-Petit I, Edouard T, Jacques V, et al.
Frontiers in endocrinology 2021; (12()):657913 doi:10.3389/fendo.2021.657913.
PMID: 34248839 - 3
Natural course of congenital hypothyroidism by dual oxidase 2 mutations from the neonatal period through puberty.
Maruo Y, Nagasaki K, Matsui K, et al.
European journal of endocrinology 2016; (174(4)):453-63 doi:10.1530/EJE-15-0959.
PMID: 26742565 - 4
Congenital Hypothyroidism: Screening and Management.
Rose SR, Wassner AJ, Wintergerst KA, et al.
Pediatrics 2023; (151(1)) doi:10.1542/peds.2022-060420.
PMID: 36827521 - 5
Mutation screening of eight genes and comparison of the clinical data in a Chinese cohort with congenital hypothyroidism.
Li L, Li X, Wang X, et al.
Endocrine 2023; (79(1)):125-134 doi:10.1007/s12020-022-03188-4.
PMID: 36125728 - 6
Double variants in TSHR and DUOX2 in a patient with hypothyroidism: case report.
Sasivari Z, Szinnai G, Seebauer B, et al.
Journal of pediatric endocrinology & metabolism : JPEM 2019; (32(11)):1299-1303.
PMID: 31541602 - 7
Permanent Congenital Hypothyroidism due to Rare Thyroglobulin Gene Variant (p.Cys1476Arg): A Delayed Diagnosis of Thyroid Dyshormonogenesis.
Mohamadsalih G, Al Bureshad K, Mohammed I, et al.
Case reports in medicine 2025; (2025()):5313611 doi:10.1155/carm/5313611.
PMID: 40453448 - 8
Congenital hypothyroidism due to thyroglobulin deficiency: a case report with a novel mutation in TG gene.
Heo S, Jang JH, Yu J
Annals of pediatric endocrinology & metabolism 2019; (24(3)):199-202 doi:10.6065/apem.2019.24.3.199.
PMID: 31607114 - 9
Molecular Analysis of Congenital Hypothyroidism in Saudi Arabia: SLC26A7 Mutation Is a Novel Defect in Thyroid Dyshormonogenesis.
Zou M, Alzahrani AS, Al-Odaib A, et al.
The Journal of clinical endocrinology and metabolism 2018; (103(5)):1889-1898 doi:10.1210/jc.2017-02202.
PMID: 29546359 - 10
Increased Prevalence of TG and TPO Mutations in Sudanese Children With Congenital Hypothyroidism.
Bruellman RJ, Watanabe Y, Ebrhim RS, et al.
The Journal of clinical endocrinology and metabolism 2020; (105(5)) doi:10.1210/clinem/dgz297.
PMID: 31867598 - 11
Genetic Factors Causing Thyroid Dyshormonogenesis as the Major Etiologies for Primary Congenital Hypothyroidism: Clinical and Genetic Characterization of 33 Patients.
Liu R, Tian JL, Huang XL, Song YZ
Journal of clinical medicine 2022; (11(24)) doi:10.3390/jcm11247313.
PMID: 36555929 - 12
Congenital Hypothyroidism: A 2020-2021 Consensus Guidelines Update-An ENDO-European Reference Network Initiative Endorsed by the European Society for Pediatric Endocrinology and the European Society for Endocrinology.
van Trotsenburg P, Stoupa A, Léger J, et al.
Thyroid : official journal of the American Thyroid Association 2021; (31(3)):387-419 doi:10.1089/thy.2020.0333.
PMID: 33272083 - 13
Congenital Hypothyroidism.
Wassner AJ
Clinics in perinatology 2018; (45(1)):1-18 doi:10.1016/j.clp.2017.10.004.
PMID: 29405999 - 14
A novel homozygous thyroglobulin gene variant presenting with massive congenital goiter and neonatal airway obstruction.
Anık A, Şen Küçük K, Öztürk S, et al.
Hormones (Athens, Greece) 2026; doi:10.1007/s42000-026-00810-2.
PMID: 42463600 - 15
Clinical efficacy of multigene panels in the management of congenital hypothyroidism with gland in situ.
Park J, Joo EY, Yoo MJ, et al.
Medicine 2024; (103(29)):e38976 doi:10.1097/MD.0000000000038976.
PMID: 39029043 - 16
DUOX Defects and Their Roles in Congenital Hypothyroidism.
De Deken X, Miot F
Methods in molecular biology (Clifton, N.J.) 2019; (1982()):667-693 doi:10.1007/978-1-4939-9424-3_37.
PMID: 31172499 - 17
MECHANISMS IN ENDOCRINOLOGY: The pathophysiology of transient congenital hypothyroidism.
Peters C, Schoenmakers N
European journal of endocrinology 2022; (187(2)):R1-R16 doi:10.1530/EJE-21-1278.
PMID: 35588090 - 18
The evaluation of transient hypothyroidism in patients diagnosed with congenital hypothyroidism.
Peltek Kendirci HN, Aycan Z, Sağsak E, et al.
Turkish journal of medical sciences 2015; (45(4)):745-50.
PMID: 26422840 - 19
Newborn Screening Guidelines for Congenital Hypothyroidism in India: Recommendations of the Indian Society for Pediatric and Adolescent Endocrinology (ISPAE) - Part II: Imaging, Treatment and Follow-up.
Sudhanshu S, Riaz I, Sharma R, et al.
Indian journal of pediatrics 2018; (85(6)):448-453 doi:10.1007/s12098-017-2576-x.
PMID: 29455331 - 20
Iodide handling disorders (NIS, TPO, TG, IYD).
Targovnik HM, Citterio CE, Rivolta CM
Best practice & research. Clinical endocrinology & metabolism 2017; (31(2)):195-212 doi:10.1016/j.beem.2017.03.006.
PMID: 28648508
This page is for informational purposes only and does not constitute medical advice. Your baby's pediatric endocrinologist should interpret test results and guide treatment, including any medication changes.